MedTrace Logo

Soluble ST2 and Cardiovascular Outcome

NCT04460131 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 500

Last updated 2022-04-25

No results posted yet for this study

Summary

Cardiac surgery induces hemodynamic stress on the myocardium, and this process can be associated with significant cardiovascular morbidity and mortality. Soluble suppression of tumorigenicity 2 (sST2) is biomarker of myocardial remodeling and fibrosis; however, little is known regarding their potential association with cardiovascular events. This study aimed to investigate the release of sST2 and its association with cardiovascular events undergoing cardiac surgery.

Conditions

Interventions

DIAGNOSTIC_TEST

soluble ST2

Serum sST2 was measured on a monoclonal electrochemiluminescence immunoassay. Samples were exposed to two freeze cycles before analysed. Samples were exposed to two thawfreeze cycles before analysed.

Sponsors & Collaborators

  • Nanjing Medical University

    lead OTHER

Principal Investigators

  • Yong-feng Shao · The First Affiliated Hospital with Nanjing Medical University

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-01-01
Primary Completion
2025-12-31
Completion
2025-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04460131 on ClinicalTrials.gov